BMS in $2.3B I-O biotech biobucks buyout deal by Ben Adams Thursday, August 3, 2017 BMS will pay $300 million up front and up to $2 billion in biobucks for IFM Therapeutics.
9. Bristol-Myers Squibb by Ben Adams Bristol-Myers Squibb has long been highly regarded when it comes to its R&D—a small Big Pharma with a biotech bent, it has always funneled much money into its research budget.
